Life-expectancy of patients enrolled in phase 1 clinical trials: a systematic review of published prognostic models.
Crit Rev Oncol Hematol
; 83(2): 242-8, 2012 Aug.
Article
em En
| MEDLINE
| ID: mdl-22226569
ABSTRACT
Life-expectancy superior to 3 months is a key-eligibility criterion for contemporary oncology phase 1 trials. Nevertheless, there is no reliable and consensual guidance for estimating this criterion. We have conducted a systematic review of published studies investigating the risk factor for 90-day mortality and the inherent generated scores. Nine studies have been published on this topic. Only two of these prognostic models have been validated on an independent dataset. Most of the models are based on a very subjective and investigator-dependent parameter the performance status. The predictive performance of these prognostic models is poorly evaluated.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ensaios Clínicos Fase I como Assunto
/
Neoplasias
Tipo de estudo:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article